Navigation Links
Scripps Florida scientist awarded $1.5 million to design therapeutics with new RNA approach
Date:4/27/2012

JUPITER, FL, April 27, 2012 A scientist from the Florida campus of The Scripps Research Institute has been awarded $1.5 million from the National Institutes of Health to develop new computer-driven design methods to find new therapeutics targeting RNA.

Matthew Disney, an associate professor at Scripps Research, is the principal investigator for the four-year study.

RNA was once considered a passive messenger, used only to carry copies of the DNA needed to produce or translate proteins. All that changed when it was found that RNA could produce chemical reactions that, for example, cause proteins to fold into various forms. RNA is an increasingly important potential target for the design of small molecule therapeutics, although methods to design small molecule drugs that bind to RNA and affect its function are still in their infancy.

"The rational design of small molecules that exploit therapeutic targets from genomic sequence was one of the promises of the human genome project, but people had no idea of how to do it," Disney said. "As a result, most targetsespecially RNA targetsrepresent untapped potential."

A computer program created by Disney merges information on the interaction between small molecules (potential drugs) and RNA folds present in segments of the human genome that contribute to specific diseases. Disney said his approach differs from conventional "top-down" methods that normally screen an RNA target against a broad chemical library.

"Our bottom-up approach uses information about the small RNA motifs such as internal loops or hairpins that a small molecule ligand prefers to bind," he said.

Using this method, Disney recently successfully designed several small molecules that are strongly active against myotonic dystrophy type 1, the most common form of muscular dystrophy.

All of the tools in the new study will be available on the Internet, so they can be shared by the RNA community.
'/>"/>

Contact: Mika Ono
mikaono@scripps.edu
858-784-2052
Scripps Research Institute
Source:Eurekalert  

Page: 1

Related biology news :

1. Scripps research team solves structure of beneficial virus
2. Scripps research team sheds light on immune system suppression
3. Scripps Florida scientists awarded $1.5M to fight major water and food parasites
4. Scripps research scientists identify compounds for stem-cell production from adult cells
5. Scripps research scientists identify blood component that turns bacteria virulent
6. Scripps research team defines new painkilling chemical pathway
7. Dolphin population stunted by fishing activities, Scripps/NOAA study finds
8. Scripps Research scientists shed light on how DNA is unwound so that its code can be read
9. Scripps scientists develop first examples of RNA that replicates itself indefinitely
10. Scripps scientists create first crystal structure of an intermediate particle in virus assembly
11. Historical photographs expose decline in Floridas reef fish, new Scripps study finds
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Scripps Florida scientist awarded $1.5 million to design therapeutics with new RNA approach
(Date:4/26/2020)... ... April 23, 2020 , ... ... miniaturization, backed by FII Tech Growth managed by Fondo Italiano d’Investimento SGR, today ... market, for the development of Respira, a new non-invasive pulmonary ventilator created in ...
(Date:4/23/2020)... ... April 23, 2020 , ... Despite the current COVID-19 ... infrastructure products for the animal feed, human consumption, wastewater, and biotech sectors, and ... supply channels from overseas competitors have become weakened or shut down completely, new ...
(Date:4/22/2020)... ... April 21, 2020 , ... Captis Biotechnology, ... capital firm that provides patent development support for early stage startups. The investment ... such as ovarian cancer and precancerous pancreatic lesions with simple, accurate and practical ...
Breaking Biology News(10 mins):
(Date:5/15/2020)... ... May 15, 2020 , ... Sentien Biotechnologies, Inc., a ... Richard Ganz as Executive Chairman. Mr. Ganz will continue to lead Sentien’s Board ... as work closely with CEO Brian Miller and Sentien’s management team. , ...
(Date:5/14/2020)... ... , ... Early stages of drug discovery often depend on ... the drug’s mechanism of action (MOA). Gene expression profiling technologies like RNA sequencing ... molecular pathways. This information can complement phenotypic readouts and can be used to ...
(Date:5/5/2020)... ... 2020 , ... Smart Meter, a diabetes management ... LTE Cat-M Cellular Connected Diabetes Blood Glucose Monitor and Remote Patient Monitoring ... broadest cellular connectivity available, to provide patients with seamless connectivity to their physicians ...
(Date:4/22/2020)... and CAMBRIDGE, Mass. (PRWEB) , ... April 20, ... ... Budapest with US offices in Cambridge, MA, announced today that Omixon’s founder and ... the early commercialisation of Omixon’s flagship product Holotype HLA since 2014 before stepping ...
Breaking Biology Technology: